Charming Medical Limited Class A Ordinary Shares

NASDAQ:MCTA

Medical - Care Facilities

Healthcare
$29.36 +0.00%

+$0.00 today

Market cap
$445.55M
Beta
0.00
P/E (TTM)
414.6
EPS (TTM)
$0.07
52W Low $4.30High $31.70

Volume 0.00M

Average 0.87M

Financial health

Charming Medical Limited Class A Ordinary Shares financial health

Start with the overall verdict and the rule-based risk checks for MCTA, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Mixed

The balance sheet looks mixed, so liquidity and debt trends deserve a closer read.

Cash and investments cover debt Liquidity needs review Elevated leverage

Cash & Investments

$2.76M

Debt Cushion

$1.60M

Current Ratio

0.7x

Interest Coverage

N/A

Risk checks

2 of 10 flagged

  • Short-term liquidity

    0.7×

    Passes when: Current assets are at least 1× current liabilities

  • Debt repayable from cash flow

    8.4 yrs

    Passes when: Free cash flow could repay all debt within 5 years

  • Positive equity

    Positive

    Passes when: Shareholders' equity is above zero

  • Interest covered

    66.5×

    Passes when: Operating income is at least 1.5× interest expense

  • Near-term debt covered

    8.8×

    Passes when: Cash and short-term investments cover debt due within 12 months

  • Manageable net debt

    Net cash

    Passes when: Net debt is below 3× EBITDA

  • Tangible equity base

    0.0%

    Passes when: Goodwill and intangibles are below 50% of equity

  • Stable Altman Z-Score

    12.86 → 15.10

    Passes when: Z-Score is not falling while below the 2.99 safe zone

  • Contained stock compensation

    0.0%

    Passes when: Stock-based compensation is below 20% of operating cash flow

  • Limited dilution

    +0.0%/yr

    Passes when: Diluted share count grows less than 2% a year

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

No financial scores available.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$816,771.00

Q4 2024

1Y -69.7%

Quick Ratio

0.7x

Q4 2024

Current Ratio

0.7x

Q4 2024

Cash Ratio

0.2x

Q4 2024

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$1.16M

Q4 2024

1Y -14.3%

Debt/Equity

23.6x

Q4 2024

Debt/Assets

0.2x

Q4 2024

Interest Coverage

—

Q4 2024

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$0.00

Q4 2024

Assets

$5.36M

Q4 2024

1Y -0.4%

Liabilities

$5.31M

Q4 2024

1Y -12.4%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q4 2024).

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

+0.0%

FY2022–FY2024 compound rate

Stock-based compensation

$0

0.0% of operating cash flow

Dividends paid

None

FY 2024

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

None

FY 2024

Weighted diluted shares outstanding

Competitor health

How does Charming Medical Limited Class A Ordinary Shares compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

Agilon Health, Inc.

AGL:NYSE

$1.51B0.290.030.37—1.021.020.16

Annexon, Inc.

ANNX:NASDAQ

$614.41M0.120.090.67—5.685.683.80

Tactile Systems Technology, Inc.

TCMD:NASDAQ

$535.50M0.070.06Net cash28.213.694.032.04

The Oncology Institute, Inc.

TOI:NASDAQ

$512.91M-6.600.63Net cash—1.351.590.47

Delcath Systems, Inc.

DCTH:NASDAQ

$500.36M0.010.01Net cash—9.9810.923.97

Cross Country Healthcare, Inc.

CCRN:NASDAQ

$428.06M0.010.011.65—3.783.781.40

Simulations Plus, Inc.

SLP:NASDAQ

$374.16M0.000.00Net cash—7.677.674.59

RxSight, Inc.

RXST:NASDAQ

$208.80M0.040.040.23—9.7510.950.76

Nakamoto Inc.

NAKA:NASDAQ

$131.71M0.410.29Net cash—1.041.040.10

Questions

Financial health questions

Common questions about MCTA's balance sheet, answered from the reported figures.

Is MCTA's balance sheet healthy?

Charming Medical Limited Class A Ordinary Shares (MCTA) has a current ratio of 0.68, a quick read on short-term liquidity.

How leveraged is MCTA?

Debt to equity is 23.57, which helps judge how much financing risk sits on the balance sheet.